Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00250679 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
A Phase 3 study of Chronic Obstructive Pulmonary Disease and Emphysema, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 443
- Enrollment target
- 20
- Study locations
NCT00250679: Completed Phase 3 study of Chronic Obstructive Pulmonary Disease and Emphysema, sponsored by Sumitomo Pharma America.
NCT00250679 is a Phase 3 study of Chronic Obstructive Pulmonary Disease and Emphysema that has completed, run by Sumitomo Pharma America. The registered enrollment target is 443 participants, below the 1,749-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00250679, a Phase 3 study of Chronic Obstructive Pulmonary Disease and Emphysema, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 443 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).
Primary Outcome
Percent of participants with the adverse event specified. SOC = system organ class.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Arformoterol tartrate inhalation solution
- DRUG Arformoterol 25 ųg BID
- DRUG Formoterol 12 ųg BID
Study Locations (20)
California
- - Carmichael
- - Fullerton
- - Long Beach
- - Paramount
- - Rancho Mirage
- - San Diego
- - Walnut Creek
Florida
- - Bay Pines
- - Brandon
- - Gainesville
- - Panama City
- - Tampa
Alabama
- - Birmingham
- - Jasper
- - Mobile
Georgia
- - Atlanta
- - Marietta
Arkansas
- - Little Rock
Colorado
- - Denver
Connecticut
- - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 443 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
What the finished NCT00250679 record still lists
NCT00250679 is an interventional study that assigns participants to a tested intervention. The registered 443 participants enrollment target is mid-sized for trials with a published cap, below the 1,749-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00250679 names 20 study sites across 7 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00250679 about?
NCT00250679 is a clinical study titled "Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease". To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT00250679?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 443 participants. The study started on 2005-10. Estimated completion is 2007-10.
What conditions does trial NCT00250679 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease, Emphysema, Bronchitis.
What interventions are being tested in trial NCT00250679?
The interventions under investigation include: Placebo (DRUG), Arformoterol tartrate inhalation solution (DRUG), Arformoterol 25 ųg BID (DRUG), Formoterol 12 ųg BID (DRUG).
Who is sponsoring clinical trial NCT00250679?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00250679 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00250679's enrollment target sits among peer trials
443 25th of 86 higher than 62 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
ACTIVE NOT RECRUITING · Phase 3
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 3
-
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06780670 · 443 participants · Phase 2
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
- NCT06700343 · 444 participants · Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
- NCT03704766 · 442 participants · NA
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia